The capital infusion will also serve to further the development of other innovative magnetic resonance image analysis technologies designed to increase physician productivity and accuracy, improve patient outcomes, and enhance research and drug development advances.
To continue Diagnosoft’s commitment to cardiovascular imaging advances, the company’s board of directors has appointed Firas BenAchour as president and CEO of Diagnosoft and a member of the board.
Mr BenAchour said: I am delighted to be appointed president and CEO of Diagnosoft, and I am very excited about the opportunities and the growth potential of our company. Since joining Diagnosoft, my principal focus has been to establish our growth strategy for the benefit of our clients, employees and investors.
We are currently focusing on organizing our client services efforts, establishing our sales and business development processes, solidifying our brand and continuing to make improvement to the quality, usability and reliability of our software solutions.